RU2011117335A - Ангонисты периферических рецепторов опиоидов и их применения - Google Patents
Ангонисты периферических рецепторов опиоидов и их применения Download PDFInfo
- Publication number
- RU2011117335A RU2011117335A RU2011117335/15A RU2011117335A RU2011117335A RU 2011117335 A RU2011117335 A RU 2011117335A RU 2011117335/15 A RU2011117335/15 A RU 2011117335/15A RU 2011117335 A RU2011117335 A RU 2011117335A RU 2011117335 A RU2011117335 A RU 2011117335A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- filled syringe
- liquid composition
- less
- tungsten
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Abstract
1. Предварительно заполненный шприц, содержащий жидкую композицию, содержащую соединение формулы III: ! ! где A- представляет собой соответствующий анион; ! и где предварительно заполненный шприц по существу не содержит вольфрама. ! 2. Предварительно заполненный шприц по п.1, в котором жидкая композиция содержит меньше, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей соединения формулы II: ! ! где X- представляет собой соответствующий анион. ! 3. Предварительно заполненный шприц по п.2, в котором жидкая композиция содержит меньше, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей, в целом соединения формулы II и соединения формулы IV: ! ! где R1 и R2 представляют собой, каждый, независимо C1-6 алифатическую группу и ! X- представляет собой соответствующий анион. ! 4. Предварительно заполненный шприц, содержащий жидкую композицию, содержащую соединение III-1: ! ! и где предварительно заполненный шприц по существу не содержит вольфрама. ! 5. Предварительно заполненный шприц по п.4, в котором жидкая композиция содержит меньше, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей соединения II-1: ! ! 6. Предварительно заполненный шприц по п.5, содержащий меньше, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей, в целом, соединения II-1 и соединения IV-1: ! ! 7. Предварительно заполненный шприц, содержащий жидкую композицию, содержащую 8 мг соединения III-1: ! ! в 0,4 мл воды и соединение II-1: ! ! где соединение II-1 присутствует в количестве �
Claims (20)
3. Предварительно заполненный шприц по п.2, в котором жидкая композиция содержит меньше, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей, в целом соединения формулы II и соединения формулы IV:
где R1 и R2 представляют собой, каждый, независимо C1-6 алифатическую группу и
X- представляет собой соответствующий анион.
7. Предварительно заполненный шприц, содержащий жидкую композицию, содержащую 8 мг соединения III-1:
в 0,4 мл воды и соединение II-1:
где соединение II-1 присутствует в количестве меньше, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей, и где предварительно заполненный шприц по существу не содержит вольфрама.
8. Предварительно заполненный шприц по п.7, в котором жидкая композиция дополнительно содержит 2,6 мг хлорида натрия, 0,16 мг кальция динатрия эдетата и 0,12 мг гидрохлорида глицина.
9. Предварительно заполненный шприц, содержащий жидкую композицию, содержащую 12 мг соединения III-1:
в 0,6 мл воды и соединение II-1:
где соединение II-1 присутствует в количестве меньшем, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей, и где предварительно заполненный шприц по существу не содержит вольфрама.
10. Предварительно заполненный шприц по п.9, в котором жидкая композиция дополнительно содержит 3,9 мг хлорида натрия, 0,24 мг кальция динатрия эдетата и 0,18 мг гидрохлорида глицина.
11. Способ, включающий стадии:
(i) обеспечения предварительно заполненного шприца, по существу не содержащего вольфрама, содержащего стандартную дозу жидкой композиции, содержащей 8 мг соединения III-1:
в 0,4 мл воды и соединение II-1:
где соединение II-1 присутствует в количестве меньшем, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей;
(ii) введения стандартной дозы субъекту путем подкожной инъекции.
12. Способ по п.11, в котором субъект страдает от запора, вызванного опиоидами.
13. Способ по п.11, в котором вольфрам присутствует в количестве меньшем, чем 50 миллиардных частей.
14. Способ по п.13, в котором вольфрам присутствует в количестве меньшем, чем 12 миллиардных частей.
15. Способ по п.11, в котором жидкая композиция дополнительно содержит кальций динатрий эдетат и гидрохлорид глицина.
16. Способ, включающий стадии:
(i) обеспечения предварительно заполненного шприца, по существу не содержащего вольфрама, содержащего стандартную дозу жидкой композиции, содержащей 12 мг соединения III-1:
в 0,6 мл воды и соединение II-1:
где соединение II-1 присутствует в количестве меньшем, чем примерно 25, примерно 100, примерно 125, примерно 150, примерно 185, примерно 187 или примерно 190 млн.частей;
(ii) введения стандартной дозы субъекту путем подкожной инъекции.
17. Способ по п.16, в котором субъект страдает от запора, вызванного опиоидами.
18. Способ по п.16, в котором вольфрам присутствует в количестве меньшем, чем 50 миллиардных частей.
19. Способ по п.18, в котором вольфрам присутствует в количестве меньшем, чем 12 миллиардных частей.
20. Способ по п.16, в котором жидкая композиция дополнительно содержит кальций динатрий эдетат и гидрохлорид глицина.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10120108P | 2008-09-30 | 2008-09-30 | |
US61/101,201 | 2008-09-30 | ||
US22658109P | 2009-07-17 | 2009-07-17 | |
US61/226,581 | 2009-07-17 | ||
US23742809P | 2009-08-27 | 2009-08-27 | |
US61/237,428 | 2009-08-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013157119/15A Division RU2013157119A (ru) | 2008-09-30 | 2013-12-23 | Антагонисты периферических рецепторов опиоидов и их применения |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2011117335A true RU2011117335A (ru) | 2012-11-10 |
Family
ID=41351442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011117335/15A RU2011117335A (ru) | 2008-09-30 | 2009-09-30 | Ангонисты периферических рецепторов опиоидов и их применения |
RU2013157119/15A RU2013157119A (ru) | 2008-09-30 | 2013-12-23 | Антагонисты периферических рецепторов опиоидов и их применения |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013157119/15A RU2013157119A (ru) | 2008-09-30 | 2013-12-23 | Антагонисты периферических рецепторов опиоидов и их применения |
Country Status (19)
Country | Link |
---|---|
US (7) | US8247425B2 (ru) |
EP (4) | EP2356119A1 (ru) |
JP (5) | JP5719773B2 (ru) |
KR (2) | KR101566675B1 (ru) |
CN (3) | CN103833634A (ru) |
AR (1) | AR073520A1 (ru) |
AU (1) | AU2009298500B2 (ru) |
BR (2) | BR122020013665B1 (ru) |
CA (1) | CA2676881C (ru) |
ES (1) | ES2914884T3 (ru) |
HK (1) | HK1199442A1 (ru) |
IL (2) | IL211865A (ru) |
MX (2) | MX2018015087A (ru) |
NZ (3) | NZ591859A (ru) |
PL (1) | PL3608322T3 (ru) |
PT (1) | PT3608322T (ru) |
RU (2) | RU2011117335A (ru) |
SG (1) | SG194393A1 (ru) |
WO (1) | WO2010039851A1 (ru) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104383542B (zh) | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
MX2009010552A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Antagonistas de receptor de opioide periferico y usos de los mismos. |
AU2008233133B2 (en) | 2007-03-29 | 2014-03-27 | Progenics Pharmaceuticals, Inc. | Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof |
MX2009010515A (es) | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
EP2164960A2 (en) | 2007-05-25 | 2010-03-24 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
KR101581480B1 (ko) | 2008-02-06 | 2015-12-30 | 프로제닉스 파머슈티컬스, 인코포레이티드 | (r),(r)-2,2'-비스-메틸날트렉손의 제조법 및 용도 |
AU2016201221B2 (en) * | 2008-09-30 | 2017-08-10 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US9082806B2 (en) | 2008-12-12 | 2015-07-14 | Stats Chippac, Ltd. | Semiconductor device and method of forming a vertical interconnect structure for 3-D FO-WLCSP |
US9064936B2 (en) | 2008-12-12 | 2015-06-23 | Stats Chippac, Ltd. | Semiconductor device and method of forming a vertical interconnect structure for 3-D FO-WLCSP |
MX349145B (es) | 2010-03-11 | 2017-07-14 | Wyeth Llc * | Formulaciones orales y sales lipofilicas de metilnaltrexona. |
MX363226B (es) * | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
CN102525911B (zh) * | 2012-03-20 | 2013-09-18 | 南京臣功制药股份有限公司 | 一种溴甲纳曲酮注射液及其制备方法 |
CA2875384A1 (en) * | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
EP3718404A1 (en) | 2014-10-17 | 2020-10-07 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progession |
US20190292246A1 (en) | 2016-11-03 | 2019-09-26 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia imhibitor |
MA48781A (fr) | 2017-06-02 | 2020-04-08 | Juno Therapeutics Inc | Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
JP7307067B2 (ja) * | 2017-12-12 | 2023-07-11 | ザルード セラピューティクス インコーポレイテッド | モルフィナンのハロゲン化誘導体およびその使用 |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
MX2021006244A (es) | 2018-11-30 | 2021-09-10 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva. |
JP2023504737A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | B細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法 |
JP7432048B1 (ja) | 2022-11-06 | 2024-02-15 | ヘイリー マーク | ペイロードを届けるスカイダイビングロボットのための装置、システムおよび方法 |
Family Cites Families (258)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1420015B1 (de) | 1959-10-16 | 1971-08-26 | Boehringer Sohn Ingelheim | 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane |
GB1202148A (en) | 1968-03-06 | 1970-08-12 | Sankyo Co | Pharmaceutical compositions |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3714159A (en) | 1971-03-30 | 1973-01-30 | Janssen Pharmaceutica Nv | 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides |
US3884916A (en) | 1971-03-30 | 1975-05-20 | Janssen Pharmaceutica Nv | 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides |
US4025652A (en) | 1975-03-31 | 1977-05-24 | William H. Rorer, Inc. | Amidinoureas |
US4326074A (en) | 1972-09-22 | 1982-04-20 | William H. Rorer, Inc. | Amidinoureas |
US3937801A (en) | 1973-07-10 | 1976-02-10 | American Home Products Corporation | Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs |
US4060635A (en) | 1975-03-31 | 1977-11-29 | William H. Rorer, Inc. | Amidinoureas for treating diarrhea |
US4203920A (en) | 1975-03-31 | 1980-05-20 | William H. Rorer, Inc. | Amidinoureas |
US4072686A (en) | 1975-04-16 | 1978-02-07 | G. D. Searle & Co. | 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols |
US4066654A (en) | 1975-04-16 | 1978-01-03 | G. D. Searle & Co. | 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives |
US3996214A (en) | 1976-02-23 | 1976-12-07 | G. D. Searle & Co. | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto |
US4013668A (en) | 1976-03-10 | 1977-03-22 | G. D. Searle & Co. | 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds |
US4012393A (en) | 1976-03-22 | 1977-03-15 | G. D. Searle & Co. | 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5 |
US4115400A (en) | 1976-05-27 | 1978-09-19 | Eli Lilly And Company | 1-Azoniabicyclo[3.1.0]hexanes |
US4176188A (en) * | 1976-11-18 | 1979-11-27 | Ortho Pharmaceutical Corp. | Utero-evacuants |
GB1593191A (en) | 1977-03-23 | 1981-07-15 | Reckitt & Colmann Prod Ltd | Derivatives of morphine |
US4125531A (en) | 1977-04-18 | 1978-11-14 | G. D. Searle & Co. | 2-Substituted-1-azabicyclo[2.2.2]octanes |
US4069223A (en) | 1977-05-02 | 1978-01-17 | G. D. Searle & Co. | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof |
US4116963A (en) | 1977-05-23 | 1978-09-26 | G.D. Searle & Co. | 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds |
US4194045A (en) | 1977-12-27 | 1980-03-18 | G. D. Searle & Co. | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds |
IT1096665B (it) | 1978-06-14 | 1985-08-26 | Tecnofarmaci Spa | Composizione farmaceutica per la terapia di stati di frigidita' ed impotenza |
US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
US4311833A (en) | 1979-03-06 | 1982-01-19 | Daicel Chemical Industries Ltd. | Process for preparing ethylcarboxymethylcellulose |
US4277605A (en) | 1980-03-07 | 1981-07-07 | Bristol-Myers Company | Chemical compounds |
US4322426A (en) | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4466968A (en) | 1980-11-24 | 1984-08-21 | Dermall, Ltd. | Method for prophylaxis or treatment of emesis and nausea |
US4427676A (en) | 1980-12-19 | 1984-01-24 | John Wyeth & Brother Ltd. | Thiomorpholine derivatives |
US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
US4870084A (en) | 1982-03-16 | 1989-09-26 | Pfizer Inc. | Bicyclic benzo fused pyran compounds used for nausea treatment and prevention |
US4430327A (en) | 1982-05-18 | 1984-02-07 | Eli Lilly And Company | Method for treating pregnant females for pain and anxiety |
US4457907A (en) | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
US4533739A (en) | 1982-10-12 | 1985-08-06 | G. D. Searle & Co. | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity |
US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4462839A (en) | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US4666716A (en) | 1984-09-04 | 1987-05-19 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
JPS6229515A (ja) | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | 硬カプセル剤のフイルムコ−テイング方法 |
JPH0676314B2 (ja) | 1985-09-30 | 1994-09-28 | 花王株式会社 | 坐剤基剤及び坐剤 |
US4824853A (en) | 1985-10-11 | 1989-04-25 | Janssen Pharmaceutica N.V. | α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea |
US4806556A (en) | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
DE3609073C2 (de) | 1986-03-18 | 1995-08-10 | Hans J Prof Dr Rer Nat Schmitt | Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten |
US4990521A (en) | 1986-07-03 | 1991-02-05 | Janssen Pharmaceutica | 4-(aroylamino)piperidine-butanimide derivatives |
EP0319545B1 (en) | 1986-08-28 | 1992-03-18 | Enzacor Properties Limited | Animal growth promotant |
US5597564A (en) | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
US4888346A (en) | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
US4765978A (en) | 1986-12-16 | 1988-08-23 | Schering Corporation | Novel vaginal suppository |
FR2609632B1 (fr) | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
NL8700842A (ru) | 1987-04-10 | 1988-11-01 | Duphar Int Res | |
US4891379A (en) | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
US4857833A (en) | 1987-08-27 | 1989-08-15 | Teradyne, Inc. | Diagnosis of faults on circuit board |
CA1315689C (en) | 1987-09-03 | 1993-04-06 | Leon I. Goldberg | Quarternary derivatives of noroxymorphone which relieve nausea and emesis |
ES2051742T3 (es) | 1987-09-10 | 1994-07-01 | Univ Chicago | Derivados cuaternarios de noroxi-morfina que mitigan las nauseas y la emesis. |
US4912114A (en) | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
US5312899A (en) | 1988-06-30 | 1994-05-17 | Biochem Pharma, Inc. | Dermorphin analogs |
JPH0653683B2 (ja) | 1988-07-14 | 1994-07-20 | ザ ロックフェラー ユニバーシティ | 慢性痛あるいは慢性咳を治療する経口用組成物 |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4999342A (en) | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
US4857533A (en) | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
US4863928A (en) | 1989-01-04 | 1989-09-05 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for arthritic and inflammatory diseases |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5116868A (en) | 1989-05-03 | 1992-05-26 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US4965269A (en) | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
US5236947A (en) | 1990-02-28 | 1993-08-17 | Jouveinal S.A. | Propanamines, their pharmacological properties and their application as an antidiarrheal |
JPH0813748B2 (ja) | 1990-04-23 | 1996-02-14 | 帝國製薬株式会社 | 大腸崩壊性ポリペプチド系経口製剤 |
KR970005839B1 (ko) | 1990-05-11 | 1997-04-21 | 화이자 인코포레이티드 | 상승 치료효과를 얻기 위한 조성물 및 방법 |
JP3160862B2 (ja) | 1990-11-15 | 2001-04-25 | 雪印乳業株式会社 | 骨強化食品、飼料及び医薬 |
JPH04230625A (ja) | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
DE69231274T2 (de) | 1991-02-25 | 2000-11-30 | Univ Boston | Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist |
JP2916290B2 (ja) | 1991-03-22 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ポリペプチド含有大腸崩壊経口製剤 |
US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
CA2064373C (en) | 1991-03-29 | 2005-08-23 | Buddy Eugene Cantrell | Piperidine derivatives |
US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
US5220017A (en) | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
WO1993000077A1 (en) | 1991-06-21 | 1993-01-07 | University Of Cincinnati | Orally administrable therapeutic proteins and method of making |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5614219A (en) | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
US5256154A (en) | 1992-01-31 | 1993-10-26 | Sterling Winthrop, Inc. | Pre-filled plastic syringes and containers and method of terminal sterilization thereof |
JPH05213763A (ja) | 1992-02-10 | 1993-08-24 | Sanwa Kagaku Kenkyusho Co Ltd | 易吸収活性化カルシウム製剤 |
DE4294862T1 (de) | 1992-04-10 | 1994-06-09 | Vni Skij I Medicinskich Polime | Pharmazeutische Komposition |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
USRE36547E (en) | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
SG52402A1 (en) | 1992-12-22 | 1998-09-28 | Univ Cincinnati | Oral administration of immunologically active biomolecules and other therapeutic proteins |
DE4303214A1 (de) | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5656290A (en) | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US5391372A (en) | 1993-06-28 | 1995-02-21 | Campbell; Elizabeth | Methods of treating colic and founder in horses |
NZ268969A (en) | 1993-07-23 | 1997-06-24 | Toray Industries | Morphinan derivatives and pharmaceutical compositions |
GB2281205A (en) | 1993-08-24 | 1995-03-01 | Euro Celtique Sa | Oral opioid analgesic |
SE9303744D0 (sv) | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
DE69503126T2 (de) | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
IT1269826B (it) | 1994-05-24 | 1997-04-15 | Paolo Minoia | Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate |
US5536507A (en) | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
US5866154A (en) | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
US5614222A (en) | 1994-10-25 | 1997-03-25 | Kaplan; Milton R. | Stable aqueous drug suspensions and methods for preparation thereof |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
ES2094694B1 (es) | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
US6096763A (en) | 1995-02-23 | 2000-08-01 | Merck & Co., Inc. | α1a adrenergic receptor antagonists |
US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
GB9517001D0 (en) | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
US5804595A (en) | 1995-12-05 | 1998-09-08 | Regents Of The University Of Minnesota | Kappa opioid receptor agonists |
DK0780372T3 (da) | 1995-12-21 | 2002-03-11 | Syngenta Participations Ag | 3-Amino-2-mercaptobenzoesyrederivater samt fremgangsmåder til deres fremstilling |
KR100469029B1 (ko) | 1996-02-15 | 2005-05-27 | 얀센 파마슈티카 엔.브이. | 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도 |
DE69709646T2 (de) | 1996-03-12 | 2002-08-14 | Alza Corp | Zusammensetzung und dosisform mit einem opioid-antagonisten |
US6136780A (en) | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
US20010036469A1 (en) | 1997-01-13 | 2001-11-01 | Gooberman Lance L. | Opiate antagonist implant and process for preparation therefor |
WO1998035679A1 (de) | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilisierung von naloxonhydrochlorid |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
HU9701081D0 (en) | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
US6525038B1 (en) | 1997-06-24 | 2003-02-25 | Werner Kreutz | Synergistic compositions for the selective control of tumor tissue |
US6353004B1 (en) | 1997-07-14 | 2002-03-05 | Adolor Coporation | Peripherally acting anti-pruritic opiates |
US6096764A (en) | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
US6099853A (en) | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US20030158220A1 (en) | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
AU2003204844B2 (en) | 1997-11-03 | 2007-06-07 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
EP0913152B1 (de) | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
EP0930334A1 (en) | 1998-01-16 | 1999-07-21 | Quest International B.V. | Polysaccharide conjugate capable of binding cellulose |
GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
PT1068870E (pt) | 1998-04-03 | 2006-10-31 | Ajinomoto Kk | Agentes antitumorais |
US6359111B1 (en) | 1998-05-28 | 2002-03-19 | Neorx Corporation | Opioid receptor targeting |
HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
US20010010919A1 (en) | 1998-10-13 | 2001-08-02 | David K. Grandy | Opioid antagonists and methods of their use |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
US7129265B2 (en) | 1999-04-23 | 2006-10-31 | Mason R Preston | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
US6171620B1 (en) | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US20020068712A1 (en) | 1999-07-23 | 2002-06-06 | Troy Stevens | Use of decreasing levels of functional transient receptor potential gene product |
US20030105121A1 (en) | 1999-07-27 | 2003-06-05 | Bernard Bihari | Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents |
CA2380524A1 (en) | 1999-08-25 | 2001-03-01 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
ES2226886T3 (es) | 1999-08-31 | 2005-04-01 | Grunenthal Gmbh | Forma de administracion de accion retardada que contiene sacarinato de tramadol. |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
DE60013630T2 (de) | 1999-11-01 | 2005-09-15 | John Cardiff Rhodes | Arzneimittel zur behandlung von darmverstopfung und reizkolon |
ES2251168T3 (es) | 1999-11-04 | 2006-04-16 | Institut Gustave Roussy | Agente antiviral en combinacion con radioterapia para el tratamiento del cancer. |
US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
DK1244448T3 (da) | 1999-11-29 | 2009-08-17 | Adolor Corp | Nye metoder til behandling og forebyggelse af ileus |
DK1244447T3 (da) | 1999-11-29 | 2007-04-23 | Adolor Corp | Nye fremgangsmåder og sammensætninger indeholdende opioider og deres antagonister |
AU4136901A (en) | 1999-11-29 | 2001-06-18 | Adolor Corporation | Novel methods for the treatment and prevention of dizziness and pruritus |
US6384044B1 (en) | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
US20010046968A1 (en) | 2000-03-23 | 2001-11-29 | Zagon Ian S. | Opioid growth factor modulates angiogenesis |
US6967075B2 (en) | 2000-04-07 | 2005-11-22 | Schering Corporation | HCV replicase complexes |
WO2001085257A2 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
EP1175905A1 (en) | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
FI116089B (sv) | 2000-07-27 | 2005-09-15 | Johan Tore Karlstroem | Anordning och förfaranden vid reglar |
RS50397B (sr) | 2000-07-28 | 2009-12-31 | F. Hoffmann-La Roche Ag., | Farmaceutska smeša |
JP4183371B2 (ja) | 2000-08-31 | 2008-11-19 | 日本・バイオ株式会社 | 発酵ウコンの製造法 |
NZ507152A (en) | 2000-09-27 | 2001-06-29 | Hiltive Pty Ltd | Wall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members |
AU2002249885A1 (en) | 2000-11-17 | 2002-08-12 | Adolor Corporation | Delta agonist analgesics |
US6967016B2 (en) | 2000-12-04 | 2005-11-22 | Primagen Holding B.V. | Method of determining therapeutic activity and/or possible side-effects of a medicament |
MXPA03005135A (es) | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon. |
US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
WO2002076472A2 (en) | 2001-03-23 | 2002-10-03 | Shire Biochem Inc. | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
US20040242523A1 (en) | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
WO2002080987A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
EP2283845A1 (en) | 2001-04-26 | 2011-02-16 | pSivida Inc. | Sustained release drug delivery system containing codrugs |
US20030022909A1 (en) | 2001-06-05 | 2003-01-30 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
US8012517B2 (en) | 2001-08-31 | 2011-09-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice Morinda citrifolia |
EP2939696B1 (en) | 2001-10-18 | 2016-03-09 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
US20030144312A1 (en) | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
WO2003037365A1 (en) | 2001-11-01 | 2003-05-08 | The Johns Hopkins University | Methods and compositions for treating vascular leak using hepatocyte growth factor |
CA2470519C (en) | 2001-12-21 | 2009-11-17 | Merck & Co., Inc. | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
US20040259898A1 (en) | 2002-02-04 | 2004-12-23 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
US20050011468A1 (en) | 2002-02-04 | 2005-01-20 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
WO2003077867A2 (en) | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
US7355081B2 (en) | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
US7329642B2 (en) | 2002-05-17 | 2008-02-12 | Board Of Regents, University Of Texas System | β-2-glycoprotein is an inhibitor of angiogenesis |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US6986901B2 (en) | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
US20040010997A1 (en) | 2002-07-17 | 2004-01-22 | Oren Close | Guides to align masonry walls defining apertures, and methods of use |
US7160913B2 (en) | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
US7691374B2 (en) | 2002-10-23 | 2010-04-06 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
WO2004043964A2 (en) | 2002-11-08 | 2004-05-27 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
WO2004054511A2 (en) | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
WO2004054569A1 (en) | 2002-12-16 | 2004-07-01 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
US20050004155A1 (en) | 2003-04-08 | 2005-01-06 | Boyd Thomas A. | Use of methylnaltrexone to treat irritable bowel syndrome |
AU2004229464A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
CN104383542B (zh) * | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
RU2350327C2 (ru) | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Составы, вызывающие потерю веса |
US6992193B2 (en) | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
DK1644021T3 (da) | 2003-06-13 | 2012-10-29 | Ironwood Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme |
AU2003903387A0 (en) | 2003-07-02 | 2003-07-17 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
EP1682006A4 (en) | 2003-10-29 | 2011-01-26 | Physiosonics Inc | METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW |
US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
JP4225922B2 (ja) | 2004-01-15 | 2009-02-18 | アキレス株式会社 | ポリオレフィン系樹脂発泡体シート |
US20070082044A1 (en) | 2004-03-10 | 2007-04-12 | Trustees Of Tufts College | Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene |
TW200533339A (en) | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
US6946556B1 (en) | 2004-05-21 | 2005-09-20 | Acura Pharmaceuticals, Inc. | Preparation of opioid analgesics by a one-pot process |
US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
US20060204512A1 (en) | 2004-09-23 | 2006-09-14 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2006039705A2 (en) * | 2004-09-30 | 2006-04-13 | Becton, Dickinson And Company | Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith |
CN101137378A (zh) | 2005-01-20 | 2008-03-05 | 普罗热尼奇制药公司 | 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (es) | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
WO2007053194A2 (en) | 2005-06-03 | 2007-05-10 | The University Of Chicago | Modulation of cell barrier dysfunction |
CA2610951A1 (en) | 2005-06-03 | 2006-12-14 | The University Of Chicago | Modulation of microbial pathogen-host cell interactions |
MX2007015287A (es) | 2005-06-09 | 2008-02-22 | Mallinckrodt Inc | Metodo para separacion y purificacion de naltrexona por cromatografia de preparacion. |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
CA2627158A1 (en) | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2receptor antagonist |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US20070259939A1 (en) | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
US20080075771A1 (en) | 2006-07-21 | 2008-03-27 | Vaughn Jason M | Hydrophilic opioid abuse deterrent delivery system using opioid antagonists |
TW200815451A (en) | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CN101678016A (zh) | 2006-11-22 | 2010-03-24 | 普罗基因制药公司 | 4,5-环氧-吗啡烷离子类似物的n-氧化物 |
MX2009005463A (es) | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | Proceso para sintetizar analogos cuaternarios de 4,5-epoxi-morfinano y aislar sus n-estereoisomeros. |
EP2101774A2 (en) | 2006-11-22 | 2009-09-23 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
MX2009010552A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Antagonistas de receptor de opioide periferico y usos de los mismos. |
MX2009010515A (es) | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
JP5213763B2 (ja) | 2009-03-03 | 2013-06-19 | キヤノン株式会社 | レンズ鏡筒及びそれを有する光学機器 |
EP3352361B1 (en) | 2015-09-17 | 2019-11-27 | Mitsubishi Electric Corporation | Power conversion device |
-
2009
- 2009-08-27 CA CA2676881A patent/CA2676881C/en active Active
- 2009-09-29 AR ARP090103740A patent/AR073520A1/es not_active Application Discontinuation
- 2009-09-30 EP EP09740568A patent/EP2356119A1/en not_active Ceased
- 2009-09-30 PL PL19197036.7T patent/PL3608322T3/pl unknown
- 2009-09-30 EP EP20140154611 patent/EP2786997A1/en not_active Withdrawn
- 2009-09-30 BR BR122020013665-0A patent/BR122020013665B1/pt active IP Right Grant
- 2009-09-30 NZ NZ591859A patent/NZ591859A/xx unknown
- 2009-09-30 KR KR1020117009755A patent/KR101566675B1/ko active IP Right Grant
- 2009-09-30 WO PCT/US2009/059058 patent/WO2010039851A1/en active Application Filing
- 2009-09-30 NZ NZ710085A patent/NZ710085A/en unknown
- 2009-09-30 MX MX2018015087A patent/MX2018015087A/es unknown
- 2009-09-30 CN CN201410019511.8A patent/CN103833634A/zh active Pending
- 2009-09-30 KR KR1020147017013A patent/KR20140091071A/ko active Search and Examination
- 2009-09-30 RU RU2011117335/15A patent/RU2011117335A/ru not_active Application Discontinuation
- 2009-09-30 CN CN2009801477621A patent/CN102307874A/zh active Pending
- 2009-09-30 ES ES19197036T patent/ES2914884T3/es active Active
- 2009-09-30 PT PT191970367T patent/PT3608322T/pt unknown
- 2009-09-30 EP EP19197036.7A patent/EP3608322B1/en active Active
- 2009-09-30 JP JP2011530179A patent/JP5719773B2/ja active Active
- 2009-09-30 MX MX2011003400A patent/MX2011003400A/es active IP Right Grant
- 2009-09-30 US US12/570,891 patent/US8247425B2/en active Active
- 2009-09-30 SG SG2013073523A patent/SG194393A1/en unknown
- 2009-09-30 EP EP22168111.7A patent/EP4071151A1/en not_active Withdrawn
- 2009-09-30 CN CN201510760116.XA patent/CN105399673A/zh active Pending
- 2009-09-30 BR BRPI0919539A patent/BRPI0919539A2/pt not_active Application Discontinuation
- 2009-09-30 NZ NZ619972A patent/NZ619972A/en unknown
- 2009-09-30 AU AU2009298500A patent/AU2009298500B2/en active Active
-
2011
- 2011-03-22 IL IL211865A patent/IL211865A/en active IP Right Grant
- 2011-09-08 HK HK14112883.9A patent/HK1199442A1/xx unknown
-
2012
- 2012-07-11 US US13/546,500 patent/US8455644B2/en active Active
- 2012-08-09 US US13/570,836 patent/US8420663B2/en active Active
-
2013
- 2013-05-02 US US13/875,657 patent/US8822490B2/en active Active
- 2013-11-19 IL IL229507A patent/IL229507A/en active IP Right Grant
- 2013-12-23 RU RU2013157119/15A patent/RU2013157119A/ru unknown
-
2014
- 2014-07-02 US US14/322,382 patent/US9180125B2/en active Active
-
2015
- 2015-02-05 JP JP2015021581A patent/JP2015129144A/ja active Pending
- 2015-09-30 US US14/870,323 patent/US9492445B2/en active Active
-
2016
- 2016-09-26 US US15/276,347 patent/US9724343B2/en active Active
-
2017
- 2017-01-26 JP JP2017012236A patent/JP2017101053A/ja active Pending
-
2018
- 2018-10-19 JP JP2018197713A patent/JP6947713B2/ja active Active
-
2020
- 2020-08-13 JP JP2020136794A patent/JP2020196733A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011117335A (ru) | Ангонисты периферических рецепторов опиоидов и их применения | |
JP2012504635A5 (ru) | ||
CN1742731A (zh) | 治疗雌性性机能障碍的吡唑并嘧啶酮类 | |
RU2009115498A (ru) | Производное бензимидазола и его применение | |
RU2014149337A (ru) | Аналоги этомидата с улучшенными фармакокинетическими и фармакодинамическими свойствами | |
RU2005135441A (ru) | Соединения для лечения метаболических расстройств | |
MX2009007018A (es) | Ligandos para formacion de imagen de inervacion cardiaca. | |
CN1204960A (zh) | 新的稳定的以扑热息痛为基础的制剂及其制备方法 | |
EA200400154A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
CN1237106A (zh) | 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物 | |
US11117870B2 (en) | Compounds, compositions, and methods for treating diseases | |
CN1960720A (zh) | 肽类化合物治疗肌萎缩性侧索硬化的新用途 | |
EA012502B1 (ru) | Соединения, специфичные к меланокортиновым рецепторам | |
RU2014152803A (ru) | Водная фармацевтическая композиция, содержащая терапевтический агент и гуанидин, производное гуанидина, и инъекция, включающая эту композицию | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
RU2005101349A (ru) | Производные-[(индол-3-ил) карбонил] пиперазина | |
CN1326456A (zh) | 8-氮杂二环[3,.2.1]辛-2-烯及-辛烷衍生物 | |
RU2006108572A (ru) | Соединения для лечения метаболических нарушений | |
AR045939A1 (es) | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos | |
RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
RU2014120411A (ru) | Схема приема модулятора или агониста рецептора s1p | |
CA2362026A1 (en) | Method for the treatment of incontinence | |
CN105209445B (zh) | 治疗运动障碍和相关病症的方法 | |
EA200600377A1 (ru) | Новая композиция | |
RU2224765C1 (ru) | Полипептидное соединение, способы его получения, фармацевтическая композиция и способ профилактики или лечения грибковых заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160427 |